Insulin Receptor

Overview

The insulin receptor was cloned simultaneously and independently by Ullrich et al. at Genentech and Ebina et al. in 1985, revealing the unexpected preformed heterotetrameric structure — a dramatic departure from the paradigm of ligand-induced RTK dimerization established by EGF receptor studies. This architecture means insulin acts not by recruiting receptor monomers together, but by inducing a large-scale conformational rearrangement within a pre-existing dimeric complex, transmitting a mechanical signal through the transmembrane helices to activate the intracellular kinase domains.

The receptor is expressed at particularly high density in the classical insulin-responsive metabolic tissues: liver (~300,000 receptors per hepatocyte, though fewer in individual hepatocyte measurements), skeletal muscle (~100,000/myocyte), and adipose tissue (~100,000/adipocyte). However, the insulin receptor is also functionally critical in tissues not traditionally considered “insulin-responsive”: brain (hypothalamic appetite regulation, hippocampal neuroplasticity, and neuronal survival), heart (GLUT4 mediates ~30% of cardiac glucose uptake under basal conditions, rising during insulin stimulation), kidney (proximal tubular glucose reabsorption and podocyte function), and endothelium (eNOS activation and vasodilation).

The discovery that IRS-1 serine phosphorylation — triggered by mTORC1/S6K1 feedback and by PKC-θ activated by diacylglycerol from intracellular lipid overload — is the molecular mechanism of acquired insulin resistance has transformed understanding of T2DM pathogenesis. This “lipotoxic” model explains why visceral obesity (ectopic fat in liver, muscle, and pancreas) is so strongly associated with insulin resistance, and why interventions reducing ectopic lipid (caloric restriction, exercise, bariatric surgery) so dramatically improve insulin sensitivity even before significant weight loss.

Structure — α₂β₂ Heterotetramer

Mechanism of Action — Insulin Binding to Metabolic Output

  Insulin binds α-subunit extracellular domain
  (Kd ~0.1 nM at Site 1; bivalent spanning of Site 1 and Site 2)
       │
       │  Large conformational change (~20 Å movement of α-CT helices)
       │  transmitted through transmembrane helices to intracellular β-subunits
       ▼
  β-subunit kinase domains juxtaposed → trans-autophosphorylation
  Primary A-loop tyrosines: Tyr1158, Tyr1162, Tyr1163
  (removes self-inhibitory A-loop occlusion; catalytic activity ↑50–100×)
  Additional sites: Tyr972 (JM, Shc docking); Tyr1316/Tyr1322 (C-tail)
       │
       ▼
  Activated IR kinase phosphorylates IRS-1 / IRS-2 at YMXM motifs
  (multiple Tyr residues; IRS-1 has >20 Tyr phosphorylation sites)
       │
       ├── p85 subunit of PI3K binds pTyr-IRS-1 via SH2 domains
       │     │
       │     ▼  PI3K catalyzes PIP₂ → PIP₃ at inner plasma membrane leaflet
       │         │
       │         ├── PDK1 recruited → phosphorylates Akt at Thr308
       │         └── mTORC2 recruited → phosphorylates Akt at Ser473 (full activation)
       │                   │
       │                   ├── AS160/TBC1D4 → Rab10 → GLUT4 vesicle fusion
       │                   │   (~80% postprandial glucose disposal)
       │                   │
       │                   ├── FoxO1 Ser256 phosphorylation → nuclear exclusion
       │                   │   → ↓PEPCK, ↓G6Pase → hepatic glucose output falls
       │                   │
       │                   ├── GSK3β Ser9 → GSK3β inhibited → glycogen synthase
       │                   │   active → glycogen synthesis (liver + muscle)
       │                   │
       │                   ├── TSC2 → mTORC1 → S6K1 → protein synthesis
       │                   │
       │                   └── PDE3B (adipocytes) → ↓cAMP → HSL inactive
       │                       → anti-lipolysis (most insulin-sensitive effect)
       │
       └── Grb2 SH2 binds pTyr972 → Grb2-SOS → Ras → Raf → MEK → ERK1/2
             (MAPK / mitogenic pathway; growth, cell cycle, gene expression)

Negative feedback and mechanisms of insulin resistance

The insulin signalling pathway is subject to multiple negative feedback loops that, when chronically engaged, produce insulin resistance:

• mTORC1/S6K1 → IRS-1 Ser phosphorylation: Akt activates mTORC1 which activates S6K1 which phosphorylates IRS-1 at Ser302/Ser307/Ser612 → IRS-1 dissociates from IR and its Tyr residues cannot be phosphorylated → PI3K cannot be recruited. This is the dominant mechanism of obesity-induced insulin resistance: hyperinsulinaemia from β-cell compensation chronically activates this feedback.
• PKC-θ/ε → IRS-1 Ser phosphorylation: Intracellular lipid accumulation (from ectopic fatty acid deposition in muscle/liver) generates diacylglycerol (DAG) → activates novel PKC isoforms → IRS-1/IRS-2 Ser phosphorylation → insulin resistance. This lipotoxic mechanism explains why visceral adiposity is so strongly associated with T2DM.
• PTEN phosphatase: Dephosphorylates PIP₃ → PIP₂, terminating Akt signalling. Heterozygous PTEN deletion causes Cowden syndrome with insulin hypersensitivity, demonstrating that PTEN is physiologically important in limiting IR signalling.
• PTP1B (PTPN1): Protein tyrosine phosphatase 1B directly dephosphorylates activated IR β-subunit Tyr residues and IRS-1 pTyr residues. PTP1B knockout mice are insulin hypersensitive and protected from diet-induced obesity — making PTP1B a validated but challenging therapeutic target.
• Receptor internalization: Ligand-bound IR undergoes clathrin-mediated endocytosis within 5–15 min; most is recycled to the surface within 2–4 hours; a fraction is degraded. This receptor downregulation contributes to impaired insulin signalling in chronic hyperinsulinaemia.

Physiological Roles

Pathology

Connections

References

• Ullrich A, Bell JR, Chen EY, et al. Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature. 1985;313(6005):756–61. doi:10.1038/313756a0 · PubMed 2983224
• Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001;414(6865):799–806. doi:10.1038/414799a · PubMed 11742412
• Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol. 2006;7(2):85–96. doi:10.1038/nrm1837 · PubMed 16493415
• Boucher J, Kleinridders A, Kahn CR. Insulin receptor signaling in normal and insulin-resistant states. Cold Spring Harb Perspect Biol. 2014;6(1):a009191. doi:10.1101/cshperspect.a009191 · PubMed 24384568